source
- Pharma faces $500B risk as patents expire, with Merck most exposed by 2028More than $500 billion in global prescription sales could be threatened by generic competition between 2026 and 2032, according to Norstella data cited by Evaluate. Merck is the most immediately e…
- Mirum's Livmarli cuts itching in ultra-rare liver disease trial, showing significant benefitMirum Pharmaceuticals reported that its ileal bile acid transporter inhibitor Livmarli achieved a statistically significant reduction in cholestatic pruritus compared with placebo in a late‑stage s…